PubMed | 1 Neuroscience Education Institute
Type: | Journal: CNS spectrums | Year: 2013
There are several investigational drugs in development for the treatment of depression. Some of the novel antidepressants in development target monoaminergic neurotransmission in accordance with the monoamine hypothesis of depression. However, the current conceptualization of antidepressant actions is that it is the downstream effects on protein synthesis and neuroplasticity that account for therapeutic efficacy, rather than the immediate effects on synaptic monoamine levels. Thus, a number of novel agents in development directly target components of this neuroplasticity hypothesis of depression, including hypothetically overactive glutamatergic neurotransmission and dysfunctional hypothalamic-pituitary-adrenal (HPA) axis functioning.